Psychiatry and Neurology, Neurology · Las Vegas, NV
NPI
1053632992
Since 2010
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2020 Wellness Way Ste 300
Las Vegas, NV, 89106
Phone (702) 432-2233
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
37,362 services
Medicare patients, 2024
1,311
Average age 73
Drug cost, 2024
$3.0M
4,861 prescriptions
Company payments, 2025
$3,299
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jay P Mahajan was code J1568 (injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg), 12,184 times for 13 patients. In total Jay P Mahajan billed 37,362 services in 64 codes, and Medicare paid $2.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-24.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 12,184 | 13 | $36.88 | $449K |
| 95886 Electrical Nerve Conductivity | Office | 1,718 | 479 | $65.82 | $113K |
| 95923 Electrical Nerve Conductivity | Office | 563 | 473 | $85.50 | $48K |
| 96138 Behavioral Health Services | Office | 449 | 443 | $22.23 | $9,982 |
| 95816 Neurologic | Office | 404 | 400 | $271.64 | $110K |
| 95913 Electrical Nerve Conductivity | Office | 386 | 384 | $200.09 | $77K |
| 99204 Office E&M - New | Office | 369 | 369 | $106.52 | $39K |
| 99214 Office E&M - Established | Office | 327 | 302 | $87.58 | $29K |
| 93922 Duplex Scan - Extremity Arteries | Office | 317 | 162 | $57.26 | $18K |
| 92547 Vision, Hearing, and Speech Services | Office | 305 | 304 | $7.46 | $2,276 |
| 92546 Vision, Hearing, and Speech Services | Office | 305 | 304 | $92.19 | $28K |
| 92537 Test - Miscellaneous | Office | 298 | 297 | $27.43 | $8,174 |
| 92540 Vision, Hearing, and Speech Services | Office | 296 | 295 | $73.87 | $22K |
| 99213 Office E&M - Established | Office | 285 | 256 | $53.78 | $15K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 280 | 36 | $43.05 | $12K |
By year: 2022 $1.1M for 20,759 services; 2023 $1.5M for 24,913 services; 2024 $2.0M for 37,362 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jay P Mahajan prescribed most often to Medicare patients was Gabapentin, with 822 prescriptions and refills. In total Jay P Mahajan wrote 4,861 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 822 | 1,129 | 249 | $7,452 |
| Pregabalin Generic | 413 | 483 | 116 | $7,804 |
| Memantine Hcl Generic | 350 | 623 | 88 | $6,093 |
| Botox Onabotulinumtoxina | 339 | 943 | 137 | $537K |
| Levetiracetam Generic | 320 | 550 | 70 | $5,576 |
| Donepezil Hcl Generic | 274 | 488 | 72 | $1,704 |
| Lacosamide Generic | 185 | 259 | 37 | $15K |
| Lamotrigine Generic | 150 | 223 | 27 | $1,325 |
| Nortriptyline Hcl Generic | 103 | 171 | 34 | $1,034 |
| Ubrelvy Ubrogepant | 100 | 100 | 19 | $119K |
| Cyanocobalamin Injection Cyanocobalamin (Vitamin B-12) | 98 | 153 | 22 | $659 |
| Emgality Pen Galcanezumab-Gnlm | 97 | 129 | 18 | $87K |
| Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine | 96 | 102 | 27 | $673 |
| Topiramate Generic | 75 | 143 | 20 | $485 |
| Clopidogrel Clopidogrel Bisulfate | 73 | 161 | 21 | $799 |
Brand drugs: 991 claims; generic drugs: 3,870 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jay P Mahajan $3,299 ($3,299 in general payments such as food, travel and fees) from 24 companies. The largest payer was Abbvie Inc. with $979.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 42 | $979 |
| Neurocrine BioSciences, Inc. NBIX | 9 | $336 |
| UCB, Inc. UCB.BR | 8 | $256 |
| Pfizer Inc. PFE | 12 | $224 |
| Teva Pharmaceuticals USA, Inc. TEVA | 13 | $218 |
| Argenx US, Inc. ARGX | 12 | $192 |
| Abbott Laboratories ABT | 1 | $176 |
| Lundbeck LLC | 14 | $142 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $111 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.